CD40LG and myeloid sarcoma: Finally, quantitative changes from day 1 to day 60 in the ability of the participants’ IgM‐only MBC to produce TNF in response to R848 significantly distinguished those who converted to MS early in the 12 month trial versus those who relapsed late or not at all.